In conclusion, the absence of consistent changes in gene expression of tumor cells and TAMs suggests that the effects of PD-1 monotherapy in recurrent GBM are likely subtle and insufficient, highlighting the need for combination strategies and biomarker-driven patient selection in future trial designs. This evidence concerns the gene PDCD1 and glioblastoma.